TrademarkIQ íconeTrademarkIQ
Voltar para busca
Dado oficial do USPTO

BEGESAND

Sabia que essa marca já está registrada no Estados Unidos?

Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.

Active USPTO registrationTipo: VerbalEscritório: US

Snapshot rápido

BEGESAND

ST13

US500000079201532

Classe

5, 10

Pedido

79201532

Registro

5372122

Diagnóstico de risco e oportunidade

Leitura executiva para decisão de naming, protocolo e monitoramento.

Atenção: há risco ativo

Situação USPTO

Active USPTO registration

Tipo de processo

Pedido e registro

Eventos registrados

34

Atualização mais recente

12/07/2025

Classificação

Registrada

Tipo de marca

Verbal

Classes Nice

5, 10

Data de depósito

08/09/2016

Data de registro

09/01/2018

Data de expiração

-

Ação recomendada

Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.

Próximo passo

Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.

Dados completos do processo

Campos estruturados da autoridade responsável e do histórico oficial.

Data da situação

26/07/2024

Última transação

12/07/2025

Escritório responsável

United States Patent and Trademark Office

Código da situação

709

Cadastro oficial

Principal Register

Código do desenho

4

Tipo de titular

33

Localização do titular

CH

Examinador

TWOHIG,SHANNON MARIE

Unidade examinadora

N20

Localização atual

TMO LAW OFFICE 120

Titulares e representantes

Titulares

ADIENNE SA

Representantes

Monica Riva Talley Sterne, Kessler, Goldstein & Fox P.L.L.C.

Classificação técnica

Classes Nice

Classe 5Classe 10

Códigos Vienna

Sem códigos Vienna disponíveis.

Produtos e serviços

Classe 5

Pharmaceutical products for the treatment of viral and infectious diseases, for the treatment of cancer, for the prevention and treatment of cancer, for the treatment of immune system related diseases and disorders; medical preparations for the treatment of viral and infectious diseases, for the treatment of cancer, for the prevention and treatment of cancer, for the treatment of immune system related diseases and disorders; and veterinary preparations for the treatment of viral and infectious diseases, for the treatment of cancer, for the prevention and treatment of cancer, for the treatment of immune system related diseases and disorders; sanitary preparations for medical purposes; dietetic food for treating viral and infectious diseases, for treating cancer, for treating immune system related diseases and disorders, for the prevention and treatment of cancer, and substances in the nature of beverages for medical or veterinary use; monoclonal antibodies and antibody mixtures for medical use, namely, diagnostic kits consisting primarily of monoclonal antibodies for use in disease testing; monoclonal antibodies for immunomodulatory treatments, in particular for the treatment of diseases mediated by the differentiation cluster 26 molecule CD26; pharmaceutical preparations comprising as active ingredient monoclonal antibodies having immunomodulatory effects, in particular for the treatment of diseases mediated by the 26 differentiation cluster molecule CD26; dietetic foods, namely, yogurt and rice-derived products, namely, rice flour adapted for medical use, dietetic beverages adapted for medical use, food supplements, enzyme food supplements, protein food supplements, protein supplements for animals, by-products of the processing of cereals for dietetic or medical use, biological preparations for medical use, biological preparations for veterinary use, pills for medicines, namely, immunosuppressant pills, chemical preparations for medical use, namely, for the treatment of viral and infectious diseases, for the treatment of cancer, for the prevention and treatment of cancer, for the treatment of immune system related diseases and disorders, chemical preparations for veterinary use, namely, for the treatment of viral and infectious diseases, for the treatment of cancer, for the prevention and treatment of cancer, for the treatment of immune system related diseases and disorders, biological tissue cultures for medical use, biological tissue cultures for veterinary use, enzyme preparations for medical use, enzyme preparations for veterinary use, enzymes for medical use, enzymes for veterinary use, medicines for veterinary use for the treatment of viral and infectious diseases, for the treatment of cancer, for the treatment of immune system related diseases and disorders, for the prevention and treatment of cancer, remedies for veterinary use, namely, monoclonal antibodies for immunomodulatory treatments, vaccines, veterinary products in the nature of anti-infective products for veterinary use; living tissue grafts, surgical implants composed of living tissue, radiological contrast substances for medical use, diagnostic preparations for medical use, biomarker reagents for diagnosis for medical use, adjuvants for medical use, chemical preparations for pharmaceutical use, drugs for medical use, namely, for the treatment of viral and infectious diseases, for the treatment of cancer, for the prevention and treatment of cancer, for the treatment of immune system related diseases and disorders, pharmaceutical preparations, namely, elixirs for treating viral and infectious diseases, for the treatment of cancer, for the prevention and treatment of cancer, for the treatment of immune system related diseases and disorders, plant extracts for pharmaceutical use, medicinal infusions for treating viral and infectious diseases, for treating cancer, for treating immune system related diseases and disorders, for the prevention and treatment of cancer, lotions for pharmaceutical use, medicines or human medicine for the treatment of viral and infectious diseases, for the treatment of cancer, for the treatment of immune system related diseases and disorders, for the prevention and treatment of cancer, remedies for human medicine in the nature of solution for injection for the treatment of viral and infectious diseases, for the treatment of cancer, for the prevention and treatment of cancer, for the treatment of immune system related diseases and disorders, pharmaceutical preparations for skin care, pharmaceutical preparations for the treatment of viral and infectious diseases, for the treatment of cancer, for the prevention and treatment of cancer, for the treatment of immune system related diseases and disorders, syrups for pharmaceutical use for the treatment of viral and infectious diseases, for the treatment of cancer, for the prevention and treatment of cancer, for the treatment of immune system related diseases and disorders

Classe 10

Surgical, medical, dental and veterinary apparatus and instruments, namely, infusion bag, vial, syringe; needles for medical use, medical apparatus and instruments, containers for applying medicines, namely, infusion bag, vial, syringe, hypodermic syringes, syringes for medical use, pumps for medical use, namely, infusion pump

Publicações

Histórico de despachos e eventos da marca no USPTO.

34 publicações encontradas

INNT

TOTAL INVALIDATION PROCESSED BY THE IB

11/07/2025

INTS

TOTAL INVALIDATION OF REG EXT PROTECTION SENT TO IB

24/06/2025

INPC

INVALIDATION PROCESSED

24/06/2025

INTR

TOTAL INVALIDATION OF REG EXT PROTECTION CREATED

26/03/2025

C71T

CANCELLED SECTION 71

26/07/2024

REM3

COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED

09/01/2023

NREP

NEW REPRESENTATIVE AT IB RECEIVED

31/12/2021

FINO

FINAL DECISION TRANSACTION PROCESSED BY IB

01/06/2018

FICS

FINAL DISPOSITION NOTICE SENT TO IB

16/04/2018

FIMP

FINAL DISPOSITION PROCESSED

16/04/2018

FICR

FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB

09/04/2018

R.PR

REGISTERED-PRINCIPAL REGISTER

09/01/2018

NPUB

OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED

24/10/2017

PUBO

PUBLISHED FOR OPPOSITION

24/10/2017

GPNX

NOTIFICATION PROCESSED BY IB

21/10/2017

OPNS

NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB

04/10/2017

OP2R

NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB

04/10/2017

NONP

NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED

04/10/2017

CNSA

APPROVED FOR PUB - PRINCIPAL REGISTER

19/09/2017

TEME

TEAS/EMAIL CORRESPONDENCE ENTERED

29/08/2017

CRFA

CORRESPONDENCE RECEIVED IN LAW OFFICE

29/08/2017

ALIE

ASSIGNED TO LIE

23/08/2017

TROA

TEAS RESPONSE TO OFFICE ACTION RECEIVED

02/08/2017

ARAA

ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED

24/07/2017

REAP

TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED

24/07/2017

RFNT

REFUSAL PROCESSED BY IB

18/03/2017

RFCS

NON-FINAL ACTION MAILED - REFUSAL SENT TO IB

28/02/2017

RFRR

REFUSAL PROCESSED BY MPU

28/02/2017

RFCR

NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW

25/02/2017

CNRT

NON-FINAL ACTION WRITTEN

24/02/2017

MAFR

APPLICATION FILING RECEIPT MAILED

21/02/2017

DOCK

ASSIGNED TO EXAMINER

17/02/2017

NWOS

NEW APPLICATION OFFICE SUPPLIED DATA ENTERED

17/02/2017

REPR

SN ASSIGNED FOR SECT 66A APPL FROM IB

16/02/2017

Proteção contínua da sua marca

Seja avisado a cada novo depósito que ameace BEGESAND ou a sua marca.

Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.